Bactericidal activity, morphological alterations, and synergistic interactions of rufloxacin, a new fluoroquinolone, alone and in combination with its N-desmethylate d derivative (MF922)

Chemotherapy

Volumn 42, Issue 2, 1996, Pages 90-99

  Marchese, A ^a   Debbia, E A ^a   Pesce, A ^a   Schito, G C ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Bactericidal activity; Interaction with its metabolite; MF922; Rufloxacin; Synergism

Indexed keywords

DRUG METABOLITE; NORRUFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RUFLOXACIN; UNCLASSIFIED DRUG;

AEROBIC BACTERIUM; ANAEROBIC BACTERIUM; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTEROIDES FRAGILIS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENTIATION; ENTEROBACTERIACEAE; HAEMOPHILUS INFLUENZAE; MORAXELLA CATARRHALIS; NONHUMAN; PRIORITY JOURNAL; SERUM; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

EID: 0030047935     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000239427     Document Type: Article

References (22)

1. Cecchctti V, Fravolini A. Fringuelli R. Mascellani G, Pagella P, Palmioli M, Segre G, Tomi P: Quinolonecar-boxylic acids. II. Synthesis and antibacterial evaluation of 7-oxo-2,3-di-hydro-7H-pyridol[1,2.3-de][1,4]ben-zothiazine-6-carboxylic acids. J MedChem 1987:30:465-473.
2. Mattina R, Cocuzza CE, Ccsana M, Bonfiglio G: In vitro activity of a new quinolone, rufloxacin. against nosocomial isolates. Chemotherapy 1991;37:260-269.
3. Ravizzola G, Pinsi G, Pirali F, Co lombrita D, Foresti I, Peroni I, Turano A: Rufloxacin (MF' 934): In vitro and in vivo antibacterial activity. Drugs Exp Clin Res 1989:15: 11-16.
4. Wise R, Andrews JM, Natlhews R, Wostenholme M: The in-vitro activity of two new quinolones - rufloxacin and MF 961. J Antimicrob Che-mother 1992:29:649.
5. Kisicki JC, Griess RS, Ott CL, Cohen GM, McCormack RJ, Troetel WM, Imbimbo BP: Multiple-dose pharmacokinetics and safety of rufloxacin in normal volunteers. Antimicrob Agents Chemother 1992; 36:1296-1301.
6. Cogo R, Rimoldi R, Mattina R, Imbimbo BP: Steady-state pharmacokinetics of rufloxacin in elderly patients with lower respiratory tract infections. Ther Drug Monit 1992:14: 36-41.
7. Imbimbo BP, Broccali GP, Cesana M, Crema F, Attardo-Parinello G: Inter- and intrasubject variabilities in the pharmacokinetics of rufloxacin after single oral administration to healthy volunteers. Antimicrob Agents Chemother 1991:35:390-393.
8. Wise R, Johnson J, O'Sullivan N, Andrews JM, Imbimbo BP: Pharmacokinetics and tissue penetration of rufloxacin, a long acting quinolone antimicrobial agent. J Antimicrob Chemother 1991:28:905-909.
9. Wise R, Andrews JM, Imbimbo BP, Honeybourne D: The penetration of rufloxacin into sites of potential infection in the respiratory tract. J Antimicrob Chemother 1993:32:861-866.
10. Dirkscn M, Focht J, Bocrcma J: Rufloxacin once daily in acute exacerbations of chronic bronchitis. Infection 1991:19:297-300.
11. Rimoldi R, Fioretti M, Albrici A, Imbimbo BP: Pharmacokinetics of rufloxacin once daily in patients with lower respiratory tract infections. Infection 1992:20:89-93.
12. National Committee for Clinical Laboratory Standard (NCCLS): Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, ed 3. approved standard. M7-A3. Villanova, Pa., NCCLS. 1994.
13. Marchese A, Saverino D, Debbia EA, Pesce A, Schito GC: Antista-phylococcal activity of cefdinir. a new oral third-generation cephalosporin. alone and in combination with other antibiotics, at supra- and sub-MIC levels. J Antimicrob Chemother 1995:35:53-66.
14. Jorgensen JH, Redding JS, Maher LA, Howell AW: Improved medium for antimicrobial susceptibility testing of Haemophilus influenzae. J Clin Microbiol 1987:25:2105-2113.
15. National Committee for Clinical Laboratory Standard (NCCLS): Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria, ed 3, approved standard. Ml I-A3. Villanova. Pa. NCCLS. 1993.
16. Norden CW: Problems in determination of antimicrobial synergism in vitro. Rev Infect Dis 1982:4:276-281.
17. Hardy DJ, Swanson RN, Rode RA, Marsh K, Shipkowitz IN, Clement JJ: Enhancement of the in vitro activities of clarithromycin against Haemophilus influenzae by 14-hy-droxy-clarithromycin. its major metabolite in humans. Antimicrob Agents Chemother 1990:34 1407-1413.
18. Jones RN, Barry AL, Packer RR: The activity of cefotaxime and desacetylcefotaxime alone and in combination against anaerobes and staphylococci. Diagn Microbiol Infect Dis 1984:2:37S-46S.
19. Ncu IIC: Antibacterial activity of desacetylcefotaxime alone and in combination with cefotaxime. Rev Infect Dis 1982:4:S374-S378.
20. Molinari G, Saverino D, Paglia P, Debbia EA, Schito GC: Synergistic antibacterial interaction of cefotaxime and desacetylcefotaxime. J Che-mother 1991:1:6-12.
21. Diver JM, Wise R: Morphological and biochemical changes in E. eoli after exposure to ciprofloxacin. J Antimicrob Chcmother 1986:18 (suppl D):31-41.
22. Bonina L, Arena A, Cesana M, Costa GB, Mastroeni P, Carbone M: Cellular uptake and activity of ru-floxacin in different cell types and professional phagocytic cells. Int J Antimicrob Agents 1993:2:111-116.